Sunday, September 25, 2016

(LML) Passing away of Dr. Yo Yuasa, former Executive Director and Medical Director of the Sasakawa Memorial Health Foundation

Leprosy Mailing List – September 25,  2016

Ref.:  (LML)   Passing away of Dr. Yo Yuasa, former Executive Director and Medical Director of the Sasakawa Memorial Health Foundation

From:  Grace Warren, Sidney, Australia


Dear Pieter,

Thank you for that note. Yo had done his first term of leprosy with me in Hong Kong about 1969. And I later worked with him when he was in Nepal at Anandaban around 1976.

He only retired relatively recently and I understood it was some illness. How we can praise God for his care and compassion - I wish we had more like him.

Best wishes,

Grace Warren


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


Virusvrij. www.avast.com

(LML) Passing away of Dr. Yo Yuasa, former Executive Director and Medical Director of the Sasakawa Memorial Health Foundation

Leprosy Mailing List – September 25,  2016

Ref.:  (LML)   Passing away of Dr. Yo Yuasa, former Executive Director and Medical Director of the Sasakawa Memorial Health Foundation

From:  Francisco Heldfer C. Sousa, Manaus, Brazil


Dear Dr. Pieter,

 

Alfredo da Matta Foundation technical staff sends condolences to the family of Dr. Yo Yuasa. We emphasize the important contribution of Dr. Yuasa to the programs of control and elimination of leprosy in the world. Regarding to Amazonas State-Brazil, we recognize the privilege of receive his technical visits, more than once, and the opportunity of learning from him. We also emphasize in addition to his professional quality his warmth and humility toward all men.

 

Best regards

 

Dr. Francisco Helder C. Sousa

Diretor Presidente FUAM


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

 


Virusvrij. www.avast.com

Tuesday, September 20, 2016

(LML) Passing away of Dr. Yo Yuasa, former Executive Director and Medical Director of the Sasakawa Memorial Health Foundation

Leprosy Mailing List – September 20,  2016

Ref.:  (LML)   Passing away of Dr. Yo Yuasa, former Executive Director and Medical Director of the Sasakawa Memorial Health Foundation

From:  Wayne Meyers, Maryland, USA


 

Dear Pieter,

 

We sorrow with all of you who knew Dr. Yuasa on learning of his death earlier this month.  He was a wonderful friend and an enduring example of commitment, dedication and humble hard work in all he did to help people with leprosy.

 

Dr. Yuasa has left a lasting legacy, and we will miss him.  May God comfort his family, and all his friends around the world.

 

 

Wayne and Esther Meyers

wmekmeyers@comcast.net

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 


Virusvrij. www.avast.com

Sunday, September 18, 2016

(LML) A Dual Crisis: The Chemotherapy of MB Leprosy and Leprosy Control

Leprosy Mailing List – September 18,  2016

Ref.:  (LML)   A Dual Crisis: The Chemotherapy of MB Leprosy and Leprosy Control 

From:  Grace Warren, Sidney, Australia


Dear Pieter,

 

Very interested in the letters you have been showing recently. It is the same old problems - recurrent reactions and a return of clinical lesions several years after the cessation of official MB or PB therapy. I am afraid but think that the 6 and 12 month total dosage is not adequate, as I was very disturbed by those who returned after many years with obvious relapse (or was it reinfection?). I am glad surveys are now being made, in areas where very little real survey work had been done before. I was visiting and working in some areas for over 40 years!!

I have experienced that for many years, and just wish to say that I found that clofazamine is an excellent drug for these problem patients. Many patients referred to me had already had the official WHO routine treatments but who knows how regular they were??   I am aware that many patients do not like clofazamine especially if they are light skinned and have face patches but if they are serious about recovering they will usually comply. I  found that many  or the problem patients  did very well on clofazamine, alone till I got them  controlled – if they had definite ENL I would even give 300mgms daily for a  short period and then slowly grade it off. Of course ensured treating associated problems like malaria, anemia, intestinal parasites and TB. In some areas I found that routine MDT 3 drugs initially did produce problems of reaction so often we started with Clofazamine alone and then added the others after a few months.,   

This became my practice about the 1980s - but continued to be effective till early this century. I no longer travel overseas so have little idea of what is happening now. May be I am biased as I was part of the initial drug trials for clofazamine in the mid-1960s, when I worked with Dr Stanley Browne.!  But am surprised how little I hear of the use of clofazamine today.  But as I suspect this will be in the discussions at the conference I wished to throw out what could be a forgotten method of care.  Of coursed one of the advantages is the fact that we rarely see resistance to clofazamine (or maybe I ought to say we rarely saw the resistance - does it occur today?)

I would love to be at the conference - but no matter - I can still help the problem, via this computer.

Greetings to everyone and especially those I have worked with over the years past.

 

Yours sincerely, 

 

Grace  Warren


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


Virusvrij. www.avast.com

(LML) BBC News: Vaccine brings new hope to India's largest leprosy colony

Leprosy Mailing List – September 18,  2016

Ref.: (LML) BBC News: Vaccine brings new hope to India's largest leprosy colony

From:  Grace Warren, Sidney, Australia


 

Dear Pieter,


This was sent to me this week - so I hasten to send it on. I have never heard anything about it and wondered if it is really true???  And if it is, it certainly needs to be published and that the conference in China should mention it. So I decided to send that BBC article to LML. I have read carefully the article but really do not know what to think. Will be interested to hear any follow ups.

 

Have a marvelous conference.

 

Grace

-----Original Message-----
Subject: BBC News: Vaccine brings new hope to India's largest leprosy colony

With nearly 60% of all new leprosy cases being recorded in India, the
government begins an intensive programme to eliminate the dreaded disease.

Read more:
http://www.bbc.co.uk/news/world-asia-india-37316907


** Disclaimer **
The BBC is not responsible for the content of this e-mail, and anything
written in this e-mail does not necessarily reflect the BBC's views or
opinions. Please note that neither the e-mail address nor name of the sender
have been verified.


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


Virusvrij. www.avast.com

Friday, September 16, 2016

(LML) A Dual Crisis: The Chemotherapy of MB Leprosy and Leprosy Control

Leprosy Mailing Leprosy Mailing List – September 16,  2016

 

Ref.:  (LML)   A Dual Crisis:   The Chemotherapy of MB Leprosy and Leprosy Control

 

From:  Tarun Narang, Chandigarh, India


 

Dear Pieter,

 

I agree with Robert Gelber (LML, September 15, 2016). We are facing the same problem. We are getting patients who relapse within 1-2 years of completing MDT.

 

We are also seeing a subset of patients who are non-responsive to MDT. They continue to develop new lesions, while on MDT, HAVE RECURRENT or chronic Type 2 reactions, and have high Morphological index despite 12-24 months of MDT. However, these patients respond very well to the alternative regime of Rifampicin, ofloxacine and minocycline. And their morphological index becomes zero within 3 months of alternative regime. The recurrent ENL or persistent ENL also responds and they are off steroids by 1st year of treatment.

 

I quote the lines from your paper that instead of Chemotherapy of Leprosy for Control Programmes we require as a tool to eliminate leprosy a more robust chemo-therapy regime because these patients are a serious threat to the elimination of leprosy.

 

Regards

 

Tarun Narang M.D


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


Virusvrij. www.avast.com

(LML) Passing away of Dr. Yo Yuasa, former executive and medical director of the Sasakawa Memorial Health Foundation

Leprosy Mailing Leprosy Mailing List – September 16,  2016

 

Ref.:  (LML)   Passing away of Dr. Yo Yuasa, former executive and medical director of the Sasakawa Memorial Health Foundation

 

From:  Hemanta Kumar Kar, New Delhi, India


 

Dear Friends, 

 

 

Dr Yo Yuasa's demise is a great loss to all of us. His great contribution in the field of leprosy will be remembered by each of us and by the future generation.

 

 

Regards,

 

Dr. Hemanta Kumar Kar

 

Former Director, Dean, Med. Superintendent and HOD, Dermatology, P.G.I.M.E.R. and Dr Ram Manohar Lohia Hospital

Baba Kharag Singh Marg, New Delhi-110001


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


Virusvrij. www.avast.com